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Abstract
Background: The current spread of pandemic influenza A(H1N1)v virus necessitates an intensified surveillance of influenza
virus infections worldwide. So far, in many laboratories routine diagnostics were limited to generic influenza virus detection
only. To provide interested laboratories with real-time PCR assays for type and subtype identification, we present a bundle
of PCR assays with which any human influenza A and B virus can be easily identified, including assays for the detection of
the pandemic A(H1N1)v virus.
Principal Findings: The assays show optimal performance characteristics in their validation on plasmids containing the respective
assay target sequences. All assays have furthermore been applied to several thousand clinical samples since 2007 (assays for
seasonal influenza) and April 2009 (pandemic influenza assays), respectively, and showed excellent results also on clinical material.
Conclusions: We consider the presented assays to be well suited for the detection and subtyping of circulating influenza viruses.
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Introduction
Influenza A and B viruses of the orthomyxoviridae family are a cause
of significant disease burden in the human population [1–3]. In April
2009, a new variant of an influenza A(H1N1) virus (A(H1N1)v) was
identified that had never been isolated before, but spread efficiently in
the human population [4]. The sudden emergence of this new virus
not only demanded a rapid development of specific diagnostic tools,
but also challenged a diagnosticroutine that in many laboratories was
focussed on subtype-independent virus detection only. To fully assess
the epidemiological situation, a differentiation of influenza A subtypes
is necessary, especially while A(H1N1)v circulation coincides that of
seasonal influenzaviruses. Also, subtype identification can influence
decisions regarding antiviral therapy, because the different subtypes
have a differing antiviral resistance profile [5–8]. Thus, a fast
determination of the influenza A subtype can directly contribute to
patient management. We therefore present a bundle of real-time
PCR assays which enable a fast and precise determination of virus
type and subtype in respiratory specimens, including the new
influenza A(H1N1)v virus. These assays have been used successfully
by the German National Reference Center for Influenza since 2007
and April 2009, respectively.
Results
Real-time PCR assays for the detection and subtyping of
relevant human influenzaviruses were designed in consideration of
the high variability of these viruses, i.e. their most stable regions
were chosen as primer and probe targets. An assay for the subtype-
independent detection of influenza A viruses is supplemented with
a set of PCR systems that allow for a differentiation of their
hemagglutinin and neuraminidase subtypes including the newly
emerging swine influenza A(H1N1)v virus. Additionally, an
oligonucleotide set for the detection of influenza B viruses was
designed (all primer and probe sequences listed in Table 1).
For each PCR assay, a plasmid was produced that contains the
respective PCR target sequence. In case of the generic influenza A
assay (AM), plasmids were produced for different virus subtypes
that currently circulate in the human population (H1N1, H3N2,
H5N1, H1N1v) to allow for a judgement on the amplification of
all relevant influenzaviruses.
For all assays, a linear dynamic range of 10
6 to 10
1 genome
equivalents was found. Due to three oligonucleotide mismatches in
the reverse primer our original AM assay amplified the newly
emerging pandemic H1N1v virus with a reduced analytical
sensitivity as compared to the influenza A subtypes H1N1,
H3N2 and H5N1 (data not shown). Therefore, a third primer (M-
124 sw) was added to the oligonucleotide mixture in May 2009 to
compensate for these mismatches (AMsw assay). This modification
of the original AM assay increased the performance for H1N1v
significantly while preserving the performance characteristics for
the other subtypes (all validation data summarized in Table 2).
The AMsw assay shows stable amplification efficiency and a high
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The limit of detection (95% detection probability) was determined
to be around six genome equivalents per reaction. The intra- as
well as interassay variability (standard deviation of Ct values) was
shown to be #0.81 even for low copy numbers. The AMsw assay
can be duplexed with the FCV assay (Feline Calicivirus, sample
internal control) without a significant loss of performance, as only
the detection limit is minimally raised, while efficiency and
variability of AMsw remain unaltered.
Similar performance characteristics were found for the PCR
assays for subtype determination. The H1, H3, N1 and N2 assays all
have a good PCR efficiency with a high standard curve correlation
and a low assay imprecision. The 95% detection probability was
found to be between 2.81 and 6.79 genome equivalents per reaction.
The newly developed assays for the detection of H1N1v
hemagglutinin and neuraminidase genes also allow a sensitive
detection of this new virus subtype. The 95% detection probability
was shown to be 14.33 (H1v) and 9.76 (N1v) genome equivalents
per reaction, with also a high standard curve correlation and a low
assay variability.
Also for the influenza B virus assay such performance
characteristics were found. The PCR efficiency approached
100%, again with a high standard curve correlation, low assay
variability and a 95% detection probability of approximately six
genome equivalents per reaction.
Cross-reactivities were tested with all relevant influenza types
and subtypes (226pandemic A(H1N1)v, 126seasonal A(H1N1),
126A(H3N2), 66Influenza B Yamagata lineage, 66Influenza B
Victoria lineage) as well as 6 A(H5N1) isolates, 6 A(H2N2) isolates,
6 A(H7) isolates and 3 A(H9) isolates. Additionally, isolates of
Human respiratory syncytial virus A and B, Human metapneu-
movirus, Human parainfluenzavirus 1–4, Human adenovirus
types 2–4, Human coxsackievirus A6 and B1, Human enterovirus
71, Human echovirus 9, 11 and 30, Human poliovirus 1–3,
Chlamydia pneumoniae and Mycoplasma pneumoniae were
tested. Furthermore, approximately 20 human virus-negative
swab materials were examined for cross-reactivities to human
genomic DNA. No cross-reactivities were observed for either assay
with non-targeted pathogens or human genomic DNA.
All assays for the detection of seasonal influenza viruses were
validated on approximately 80–100 primary samples containing
the corresponding types and subtypes. These samples had been
diagnosed by other PCR assays and furthermore in part had been
confirmed by hemagglutination inhibition testing (HIT) after virus
culture. These validations did not indicate any problems
concerning their analytical sensitivity, their cross-reactivity or
Table 1. Primer and probe sequences.
Assay primer oligonucleotide sequence (59–39) nM segment detected viruses
AMsw M+25 AgATgAgTCTTCTAACCgAggTCg 300 M Influenza A, generic
M-124BB ccWgCAAARACATCYTCAAgTYTCTg 1200
M-124sw CTgCAAAgACACTTTCCAgTCTCTg 100
M+64 MGB FAM - TCAggCCCCCTCAA - MGB 100
BM BMP-13 gAgACACAATTgCCTACCTgC 300 M Influenza B, generic
BMP-102AN TTCCCACCRAACCARCARTgTAAT 1200
BMP-72 MGB FAM - CTgCTTTgCCTTCTC - MGB 100
H1 FluA H1 F832 ggATCAggAATCATCAMYTCAAATgC 300 HA seasonal Influenza A(H1N1)
FluA H1 R959 ggACACTCTCCTATTgTgACTgggTg 300
FluA H1 MGB914 FAM - CTgCTgTTTATAgCTCC - MGB 100
H3 H3F-162 TCCTCATCAgATCCTTgATg 300 HA seasonal Influenza A(H3N2)
H3R-291 ACAgTTgCTgTAggCTTTgC 300
H3S-284 MGB FAM - CTCTATTgggRgACCC - MGB 100
H1v FluSw H1 F236 TgggAAATCCAgAgTgTgAATCACT 300 HA pandemic Influenza A(H1N1)v
FluSw H1 R318 CgTTCCATTgTCTgAACTAgRTgTT 300
FluSw H1 TM292 FAM - CCACAATgTAggACCATgAgCTTgCTgT - BHQ1 100
N1 N1P-1078 AN AYggYAATggTgTYTggATMggRAg 1200 NA seasonal Influenza A(H1N1)
N1P-160 bp ARCTYCCRCTRTAYCCHgACCARTCRgT 1200
N1S MGB FAM - TCCAYCCRTTRggRTCCCAAA - MGB 100
N2 N2P-P-769 AN gATACTAAAATACTATTCATTgAggAgg 300 NA seasonal Influenza A(H3N2)
N2P 934 AN ATATCTACDATgggCCTATTggAgC 300
N2-S-840 MGB FAM - CAYTCCTCgACATgCTg - MGB 100
N1v FluSw N1 F1255 AgACCTTgCTTYTgggTTgAAC 300 NA pandemic Influenza A(H1N1)v
FluSw N1 R1334 AAggATATgCTgCTCCCRCTAgT 300
FluSw N1 TM1310 FAM - CAgATTgTgTTCTCTTTgggTCgCCCT - BHQ1 100
FCV FVC F54 CGTTACCGCCACACCCAT 300 n.a. Feline Calicivirus
FCV R141 GAGTTCACGAAAGATTTCAGACCAT 300
FCV TM96 TexasRed - ACCCATCATTCTAACACTCCCGCCAAT - BHQ2 100
All oligonucleotide sequences are listed in 59–39 orientation. M=Matrix, HA=Hemagglutinin, NA=Neuraminidase, n.a.=not applicable.
doi:10.1371/journal.pone.0009966.t001
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(withthe exceptionofAMswandA(H1N1)vassays)weretransferred
to our diagnostic routine procedure in 2007 (Figure 1): Before
nucleicacid extraction,FCVisaddedtothe samplematerialtoyield
approximately 50 genome equivalents per PCR template volume of
cDNA. All samples then are examined with the AM/AMsw, BM
and FCV assays. In case of a negative FCV result in an
influenzavirus-negative sample, the sample gets re-extracted and/
or a new cDNA is synthesized. In influenza A positive samples, the
hemagglutinin and neuraminidase subtypes are identified.
Since 2007, the assays for seasonal influenza viruses have been
run on approximately 1000 (N1, N2), 4000 (H1, H3) or 6000 (BM)
primary samples. Until the emergence of A(H1N1)v viruses in
April 2009 also the AM assay had been run on approximately
15000 samples, while the enhanced AMsw assays since then has
been run on approximately 4000 samples. For all assays, the
examination of primary material yielded results that were in
concordance with additional or complementary PCR assays (e.g.
assays for subtype identification) regarding Ct values and overall
results. Also, all results matched those from antigenic character-
ization (hemagglutination inhibition testing) of virus isolates after
successful virus culture. Influenza A-positive samples could always
be typed as A(H1N1), A(H3N2) or A(H1N1)v, and to our
knowledge we never received any false-positive results.
The validation of the H1v assay was performed on clinical
samples in parallel with two additional real-time PCRs (specific for
A(H1N1)v and swine influenza viruses, respectively) as well as two
conventional (nested) PCR assays that were furthermore con-
firmed by sequencing of the amplicon (Sanger sequencing or
Pyrosequencing, respectively). We continued to closely monitor
the possible occurrence of false-positive or false-negative results for
approximately the first 100 samples. By then, our validation on
H1N1v-negative material had shown that cross-reactivities to
other pathogens or human genomic DNA did not occur. We
continued to confirm H1v-positive samples by at least one of the
methods mentioned above for approximately 1000 samples. The
N1v assay was introduced into our diagnostic routine after a
regular validation on the above mentioned material as well as all
available H1v-positive samples within few weeks after the
emergence of A(H1N1)v. Since then, it has been run on
approximately 3500 samples and always yielded results in
congruence to all other PCR data.
Discussion
After the emergence of the pandemic influenza A(H1N1)v virus
in April 2009, PCR assays for the specific detection of this novel
virus variant were internationally communicated almost instantly.
Many laboratories picked up the national and international
recommendations and were able to offer A(H1N1)v PCR
diagnostics within few days or weeks. Also, PCR assays were
published very quickly [9–11], so that diagnostic expertise was
distributed further. However, especially during the early phase of
pandemic virus circulation, a co-circulation of the seasonal
influenza A (and B) viruses has to be expected, and indeed was
observed on the southern hemisphere from spring to fall 2009 [12–
15]. Therefore, precise diagnostics including subtype determination
are important for a comprehensive epidemiological surveillance.
Also, a subtype identification is relevant for appropriate patient
management, because the seasonal and pandemic influenza A
viruses cause severe disease in differing patient groups [16,17] and
have a different resistance profile [5–8]. Routine diagnostics are
often limited to influenza A (and B) virus detection, while virus
subtypingispredominantlyperformedforsurveillancepurposesand
thus mainly restricted to laboratories with public health duties. To
provide interested laboratories with methods for this task, we
present a bundle ofPCRassays to be used forsubtypeidentification.
These assays have been used by the German National Reference
Center for Influenza for the preceding influenza seasons as well as
during the emergence of the pandemic A(H1N1)v virus.
Table 2. PCR assay validation results.
Assay
a (sub)type Slope
b E
b R
2b LOD
c Reproducibility
d
Intrassay Interassay
500,000 5,000 50 500,000 5,000 50
AMsw A(H1N1) 23.18 106% 0.999 5.95 0.29 0.22 0.58 0.36 0.33 0.81
A(H3N2) 23.42 96% 0.998 4.99 0.13 0.12 0.35 0.24 0.22 0.48
A(H1N1)v 23.32 100% 0.999 7.11 0.09 0.13 0.34 0.35 0.25 0.46
A(H5N1) 23.68 87% 0.999 6.79 0.27 0.14 0.46 0.39 0.18 0.40
AMsw+FCV A(H1N1) 23.55 91% 0.999 12.81 0.19 0.13 0.59 0.20 0.44 0.61
H1 A(H1N1) 23.40 97% 0.998 2.81 0.10 0.11 0.21 0.14 0.21 0.36
H3 A(H3N2) 23.70 86% 0.997 4.92 0.14 0.21 0.46 0.25 0.29 0.54
H1v * A(H1N1)v 23.14 108% 0.987 14.33 0.12 0.27 0.67 0.22 0.29 0.52
N1 A(H1N1) 23.39 97% 0.998 6.49 0.18 0.16 0.51 0.31 0.16 0.41
N2 A(H3N2) 23.46 95% 0.999 6.79 0.18 0.10 0.28 0.16 0.09 0.54
N1v * A(H1N1)v 23.30 101% 0.999 9.76 0.32 0.21 0.55 0.29 0.32 0.64
BM B 23.27 102% 0.999 5.61 0.14 0.22 0.73 0.19 0.22 0.78
avalidation data was obtained on a Stratagene Mx3000 instrument for the assays indicated with an asterisk. All other assays were validated on a Stratagene Mx3005
instrument.
bslope, efficiency (E) and correlation (R
2) of standard curve; PCR efficiency was calculated as E=10
(21/slope)21.
cLimit of detection (LOD) was calculated as 95% detection probability by probit analyses applying the SPSS 17.0 Statistics software.
dreproducibility was calculated by examination of indicated plasmid copy numbers; intraassay: sixfold examination in a single run, interassay: twofold examination of
double reactions plus inclusion of intraassay data; standard deviation of obtained Ct values are listed.
doi:10.1371/journal.pone.0009966.t002
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targets the viral M segment and thus allows a virus detection that is
independent of the viral subtype. Its oligonucleotide design is
based on a primer/probe system described by Spackman et al.
[18]. Slight modifications of primer sequences as well as
substitution of the conventional 59-exonuclease probe with a
Minor Groove Binder (MGB) probe resulted in an assay that
amplifies influenza A subtypes H1N1, H3N2 and H5N1 with
similar analytical sensitivity and reproducibility. Unfortunately, its
performance on the pandemic H1N1v virus proved to be impaired
due to three nucleotide mismatches in the reverse primer. The
addition of a third primer to the oligonucleotide mix that perfectly
matches the H1N1v sequences yielded a significant improve in
assay performance with H1N1v viruses without reducing the
performance on the other subtypes H1N1, H3N2 and H5N1.
Also for the detection of seasonal H1 and N1 as well as H3 and
N2subtypes,PCRassaysweredesigned toimplement MGBprobes.
The MGB molecule stabilizes the DNA duplex formation by
hydrophobic interactions, which results in an increase in the probes
melting temperature and thus allows the design of shorter probes
[19]. This not only offers improved options for the detection of
highly variable sequences like those from influenzaviruses, but also
leadstoanincreaseinfluorescenceintensityand sometimesa shiftof
Ct values of several cycles when compared to conventional probes
(unpublished data). These features are especially helpful for samples
containing only few copies of viral genome, since not only the
detection limit is improved, but also the interpretation of dubious
results is simplified. We therefore prefer MGB probes to
conventional 59-exonuclease probes in real-time PCR diagnostics.
On the other hand, MGB probes are more vulnerable to nucleotide
mismatches compared to conventional probes [19], and therefore a
close monitoring of the genetic virus evolution is imperative to
ensure the suitability of the MGB assays in the future. For the same
reason we also decided to apply conventional probes for the
detection of pandemic A(H1N1) viruses, because in April 2009 the
assay designs had to be based on single sequences without any
knowledge concerning the viruses sequence variability. The
application of MGB probes might have possibly produced dubious
or false negative results in a fraction of samples in case of variable
nucleotides within the MGB’s target sequence. For these first-
generation assays we therefore consider a conventional probe to be
more suitable because of their higher tolerance to nucleotide
mismatches, but surely these assays will have to be updated or
completely changed with increasing knowledge of viral sequences
over time [20], including the design of MGB probes if possible. So
far, the high degree of viral sequence homology has not yet
necessitated these assay updates, but surely the A(H1N1)v viruses
will start to evolve like the seasonal influenza viruses when they are
confronted with an increasingly immune population.
After an extensive validation of the developed assays with
plasmid dilutions as well as defined primary sample material, each
newly developed assay was transferred to our diagnostic routine
which includes the examination of all samples with the AM/
AMsw, BM, and the FCV assays. The latter ensures a sample
check for inhibitory substances and preparation failures which
otherwise could result in false-negative diagnostic findings [21]. To
further simplify this procedure, the FCV assay was combined with
the AM assay to a duplex PCR (AM: FAM reporter, FCV:
TexasRed reporter). This duplex approach did not result in a
deterioration of PCR performance, as all relevant characteristics
remained unaltered. This finding holds also true for the modified
AMsw assay, as was demonstrated by our validation efforts.
In our lab, all influenza A-positive samples are further
characterized regarding their hemagglutinin subtype by the
application of the seasonal H1 and H3 assays. Additionally, the
corresponding N1 or N2 assay is run on a representative subset
(during peak phase of influenzavirus circulation) or even all
samples. To further simplify the diagnostic procedure we
combined the H1 and H3 as well as the N1 and N2 assays to
duplex PCRs. Preliminary data indicates that this duplexing does
not lead to relevant assay impairment, but yields results that are
comparable to the singleplex performance.
All assay validation data were generated by using dilutions of
plasmids containing the respective assay target sequences. We
consider this kind of validation to be preferable to viral cDNA
preparations because of its higher objectivity and thus compara-
bility to assay performances observed in other laboratories. The
preparation of viral cDNAs is greatly influenced by lab-specific
preparation protocols regarding RNA/cDNA quality and quan-
tity, and initial virus particle quantity can only be roughly
estimated by classical virological means like hemagglutination
inhibition testing or virus titration. Also, we found the validation
data obtained with plasmid dilutions to be very similar to data
obtained with dilutions of influenzavirus material [22], so that we
do expect this to hold true in general.
During the first days of the emergence of the pandemic A(H1N1)v
virus the described assays were used to (i) verify an infection with an
influenza A virus and (ii) exclude seasonal influenza A subtypes.
Within only four days after publication of the first viral sequences, the
Figure 1. Real-time PCR diagnostic scheme. Samples are spiked
with FCV after arrival in the lab. After nucleic acid extraction and cDNA
synthesis, all samples are examined by real-time PCR with the AM/
AMsw + FCV duplex PCR assay and the BM assay. All influenza A-
positive samples then undergo subtyping by the H1, H3 and H1v assays.
The subtype information can be completed by the application of the
corresponding N1, N2 and N1v assays. FCV-negative samples are
considered non-analyzable in case that no influenza A or B virus is
amplified, and are re-analyzed. Otherwise, samples are considered
positive for the detected virus.
doi:10.1371/journal.pone.0009966.g001
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German health authorities and laboratories. Only little time later, the
N1v assay could be included into the diagnostic routine. Both the
H1v and the N1v assay were designed not only to detect, but also to
discriminate A(H1N1)v from the seasonal A(H1N1) (and A(H3N2))
viruses. Indeed, no cross-reactivity was observed even for virus isolate
preparations with a very high virus load.
In total, we consider the presented assays to be valuable tools for
influenza virus typing and subtyping. The plasmid validation data
indicate sensitive and reproducible virus detection, while the assays
performance on thousands of clinical samples ensures their
applicability in clinical diagnostics. We therefore believe that our
set of PCR assays will greatly contribute to virus detection and
subtyping during and after the H1N1v pandemic.
Methods
Clinical samples
The clinical samples were taken from patients presenting with
influenza-like illness who gave verbal consent for virological
examination. Samples were sent to the National Reference Center
for Influenza at the Robert Koch Institute (Berlin, Germany) for
influenzavirus surveillance purposes in Germany. Consequently,
ethic committee approval was not required since such a sentinel
surveillance is covered by German legislation (Infektionsschutzge-
setz 1113, 14). Since 2007, approximately 16000 nasal and/or
throat swabs (and other materials like throat and nasal washings,
bronchoalveolar lavages etc.) have been collected.
Sample preparation, nucleic acid extraction and cDNA
synthesis
Swabs were washed out in cell culture medium either
individually or pooled per patient. RNA was extracted from
300 mL culture supernatant using the MagAttract Viral RNA M48
Kit (Qiagen) and eluted in 80 mL elution buffer. Alternatively,
RNA was extracted using the RTP DNA/RNA Virus Mini Kit
(Invitek) from 400 mL culture supernatant with an elution volume
of 60 mL. 25 mL of extracted RNA were subjected to cDNA
synthesis applying 200 U M-MLV Reverse Transcriptase (Invitro-
gen) in a total reaction volume of 40 mL.
Assay Design
Sequence alignments for the selection of PCR target regions
were generated using the BioEdit 7.0.9 software after sequence
download from NCBI (National Center for Biotechnology
Information, http://www.ncbi.nlm.nih.gov). Primer and probe
oligonucleotide sequences were designed using the Oligo 6.71 and
Primer Express 3.0 software.
Polymerase Chain Reaction
Quantitative real-time PCR was carried out on Mx3000 and
Mx3005 real-time PCR thermal cyclers (Stratagene) in a total
reaction volume of 25 mL. The reaction contained 16PCR buffer,
5 mmol/L MgCl2, 1 mmol/L dNTP (Invitrogen) with dUTP (GE
Healthcare), 0.5 U Platinum Taq Polymerase (Invitrogen), primers
(Metabion, Tib Molbiol) and probes (Applied Biosystems,
Metabion, Tib Molbiol) in differing concentrations (listed in
Table 1), and 3 mL of cDNA. After 5 minutes at 95uC for Taq
DNA polymerase activation, a total of 45 cycles consisting of
denaturation at 95uC for 15 seconds and annealing at 60uC for
30 seconds were performed. After the run, data were analyzed
using the software MxPro.
Plasmids
Fresh PCR products were cloned using the TOPO TA Cloning
Kit (Invitrogen) according to the manufacturer’s instructions.
Plasmid DNA was extracted from 1 mL of bacterial culture using
the Invisorb Spin Plasmid Mini Two Kit (Invitek) as recommend-
ed by the manufacturer. For verification of correct sequences at
the primer and probe binding sites, plasmids were sequenced using
the dye terminator chemistry (ABI-Prism Big Dye Terminators
v3.1 Cycle Sequencing Kit, Applied Biosystems) in a 3130xl
Genetic Analyzer (Applied Biosystems). The obtained sequences
were analyzed, assembled and aligned using the DNA STAR
Software Package. Plasmid preparations were diluted in l–DNA
(1 ng/mL) for PCR assay validations.
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